Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
21,136,667
-
Share change
-
+3,450,088
-
Total reported value
-
$538,561,145
-
Put/Call ratio
-
81%
-
Price per share
-
$25.48
-
Number of holders
-
93
-
Value change
-
+$102,084,479
-
Number of buys
-
71
-
Number of sells
-
18
Institutional Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q2 2020
As of 30 Jun 2020,
Kiniksa Pharmaceuticals Intern - COM (KNSA) was held by
93 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
21,136,667 shares.
The largest 10 holders included
Consonance Capital Management LP, BAKER BROS. ADVISORS LP, HILLHOUSE CAPITAL ADVISORS, LTD., VANGUARD GROUP INC, AMERIPRISE FINANCIAL INC, BlackRock Inc., Vivo Capital, LLC, Sofinnova Investments, Inc., CITADEL ADVISORS LLC, and Lion Point Capital, LP.
This page lists
93
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.